NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/02/2026
Voltar para busca
Dado oficial do USPTO
TELIX PHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
TELIX PHARMACEUTICALS
ST13
US500000079257540Classe
5, 10
Pedido
79257540
Registro
6908866
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
59
Atualização mais recente
27/02/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10
Data de depósito
14/03/2019
Data de registro
29/11/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
29/11/2022
Última transação
27/02/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
AU
Examinador
SEVERSON, JUSTIN
Unidade examinadora
M20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Telix Pharmaceuticals Limited
Representantes
Andrew S. Ehard MERCHANT & GOULD P.C.
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Chemicals for pharmaceutical use for the treatment, prevention, or diagnosis of cancer; pharmaceutical drugs for the treatment, prevention, or diagnosis of cancer; pharmaceutical preparations for the treatment of cancer; radiopharmaceutical products for use in the treatment, prevention, or diagnosis of cancer
Classe 10
Apparatus for administering pharmaceuticals for the treatment, prevention, or diagnosis of cancer, namely, medical apparatus for introducing pharmaceutical preparations into the human body for the treatment, prevention, or diagnosis of cancer; apparatus for medical purposes for the treatment, prevention, or diagnosis of cancer, namely, injection needles, injection syringes, and radiological apparatus for the treatment, prevention, or diagnosis of cancer; medical apparatus for the treatment of cancer; imaging apparatus for medical use for diagnosing cancer; drug delivery systems for the treatment, prevention, or diagnosis of cancer, namely, applicators for pharmaceutical preparations sold without medication for use in the treatment, prevention, or diagnosis of cancer
Publicações
Histórico de despachos e eventos da marca no USPTO.
59 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/04/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
16/03/2023
FIMP
FINAL DISPOSITION PROCESSED
16/03/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/02/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
29/11/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
29/11/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
13/09/2022
PUBO
PUBLISHED FOR OPPOSITION
13/09/2022
GPNX
NOTIFICATION PROCESSED BY IB
11/09/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
24/08/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
24/08/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
24/08/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
15/08/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/08/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
10/08/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/08/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
10/08/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/08/2022
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
09/08/2022
LIMS
LIMITATION OF GOODS/SERVICES FROM IB ENTERED
09/08/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
03/10/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/08/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/08/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
23/08/2021
LIMS
LIMITATION OF GOODS/SERVICES FROM IB ENTERED
15/08/2021
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
31/07/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
12/03/2021
GNFR
FINAL REFUSAL E-MAILED
12/03/2021
CNFR
FINAL REFUSAL WRITTEN
12/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/02/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/02/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/02/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
17/10/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
30/09/2020
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
30/09/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
17/08/2020
GNRT
NON-FINAL ACTION E-MAILED
17/08/2020
CNRT
NON-FINAL ACTION WRITTEN
17/08/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/07/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/07/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/01/2020
GNRT
NON-FINAL ACTION E-MAILED
12/01/2020
CNRT
NON-FINAL ACTION WRITTEN
12/01/2020
FINT
FINAL DECISION TRANSACTION PROCESSED BY IB
10/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/12/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/12/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/12/2019
RFNT
REFUSAL PROCESSED BY IB
12/07/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
14/06/2019
RFRR
REFUSAL PROCESSED BY MPU
14/06/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/05/2019
CNRT
NON-FINAL ACTION WRITTEN
29/05/2019
DOCK
ASSIGNED TO EXAMINER
23/05/2019
MAFR
APPLICATION FILING RECEIPT MAILED
14/05/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/05/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
08/05/2019
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
25/04/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TELIX PHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.